Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

A trial of 3,220 smokers puts cash rewards for quitting to the test

11

Oct 2026

A trial of 3,220 smokers puts cash rewards for quitting to the test

In a randomized trial of 3,220 medically underserved adults referred for lung cancer screening, adding financial incentives to usual care and free medication increased sustained smoking abstinence at six months. Offering free medication alone did not significantly increase quit rates, and adding a forward-looking mobile tool did not improve outcomes beyond the incentives.

A trial of 197 childcare services tested a different approach to active play

11

Oct 2026

A trial of 197 childcare services tested a different approach to active play

A trial involving 197 Australian childcare services found no significant overall improvements in guideline adherence or children’s observed physical activity and recreational screen time. Accredited services showed greater improvements in guideline adherence and before-school activity, but selection bias limits conclusions about whether accreditation caused these changes.

n6 expands global distribution footprint, bringing iconPCR™ and AutoNorm to more scientists across Europe, the Middle East, and Africa

10

Oct 2026

n6 expands global distribution footprint, bringing iconPCR™ and AutoNorm to more scientists across Europe, the Middle East, and Africa

n6, maker of the icon96™ and icon16 thermocyclers powered by iconPCR™ with AutoNorm intelligent normalization technology for next‑generation sequencing (NGS) library preparation, today announced new and expanded distribution partnerships that significantly increase access to its instruments across Europe, the Middle East, and Africa.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.